1. Home
  2. GENK vs HIND Comparison

GENK vs HIND Comparison

Compare GENK & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

HOLD

Current Price

$1.95

Market Cap

12.8M

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

HOLD

Current Price

$2.13

Market Cap

15.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENK
HIND
Founded
2011
2017
Country
United States
United States
Employees
2700
18
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
15.2M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
GENK
HIND
Price
$1.95
$2.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$4.50
$15.00
AVG Volume (30 Days)
18.3K
19.3K
Earning Date
05-13-2026
05-20-2026
Dividend Yield
1.88%
N/A
EPS Growth
62.50
N/A
EPS
N/A
N/A
Revenue
$208,380,000.00
N/A
Revenue This Year
$4.79
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.12
N/A
52 Week Low
$1.43
$1.75
52 Week High
$4.98
$12.87

Technical Indicators

Market Signals
Indicator
GENK
HIND
Relative Strength Index (RSI) 45.66 48.69
Support Level $1.72 $1.99
Resistance Level $2.31 $2.40
Average True Range (ATR) 0.14 0.13
MACD -0.02 -0.01
Stochastic Oscillator 8.97 22.22

Price Performance

Historical Comparison
GENK
HIND

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: